Aptus Pharma Ltd

Aptus Pharma Limited: Trading window closed from October 01, 2026 until completion of 48 hours after the declaration of the Financial Results for the half year ended September 30, 2026.

Meeting Details

• Date and time: Friday, 25 September 2026, 3:00–4:00 PM.
• Type/Mode: Virtual group investor interaction.
• Event/organiser: Arihant Capital Bharat Connect (RisingStars conference).
• Key company participants: Managing Director.
• Purpose: General investor interaction based on publicly available information.

AGM Details

• AGM held 14-09-2026 from 11:00 to 11:13 AM via VC/OAVM; record date 07-09-2026; shareholders on record: 899.

Resolutions

• Resolution 1 (Ordinary): Receive, consider and adopt Audited Financial Statements and reports.
• Resolution 2 (Ordinary): Re-appointment of director retiring by rotation.
• Resolution 3 (Special): Approval of preferential allotment of equity shares.

Voting results

• All resolutions passed with requisite majority; 100% in favour; no dissent; promoter interest: No for all resolutions.

Scrutinizer's report

• Consolidated Scrutinizer's Report confirms remote e-voting and AGM votes; resolutions passed.

AGM Details

• Date and time: 14 September 2026, 11:00 IST; mode: VC/OAVM.
• Live webcast of AGM proceedings and remote voting.
• Remote e-voting period: 11 Sep 2026 9:00 AM to 13 Sep 2026 5:00 PM.
• E-voting available during AGM; results to be declared later.

Ordinary Business

• Adopt Audited Financial Statements for year ended 31 March 2026.
• Re-appointment of director by rotation: Chetan Shantilal Lalseta.

Special Business

• Approval of preferential allotment of equity shares.

Voting Status

• Voting results to be declared within two working days.
• Outcome not disclosed in the filing.

Meeting Details

• Date and time: Friday, September 18, 2026, 4:00–6:00 pm.
• Event: Investor Meetings; type: group meeting with investors/analysts; venue: Mumbai (physical).
• Key participants: Managing Director (company).
• Organizer: Aptus Pharma Limited.
• Purpose: investor/analyst interaction based on publicly available information.

AGM details

• AGM to be held 14 September 2026 via VC/OAVM.
• Corrigendum to AGM notice issued on 7 September 2026.

E-voting and notices

• Remote e-voting from 11 Sep 2026 (9:00 AM) to 13 Sep 2026 (5:00 PM).

Resolutions

• Item 3: proposed preferential issue of equity shares; details in corrigendum.

Funding plan and growth strategy

• Board approves ₹44.88 crore preferential issue of equity shares, subject to AGM approval.
• Proceeds: ₹25 crore for capex (land, manufacturing facility, storage facilities, vehicles).
• ₹10 crore for working capital; ₹9.88 crore for general corporate purposes.
• Utilisation to occur within 36 months from receipt of funds.
• Long-term aim to meet about 20% of products through in-house manufacturing.
• Domestic expansion across West, Central, East and South India toward Pan-India operations.
• International expansion: explore opportunities in Africa, Middle East and Latin America via registrations and partnerships.

Business model

• Asset-light, marketing- and distribution-led model with two Gujarat loan-license facilities.
• 250+ formulations across Pharma Formulation, OTC/Wellness, and International verticals.
• Rx-brand focus with doctor engagement; export services via international vertical.

Financial performance

• FY26 revenue ₹46.57 crore; YoY growth 89.7%.
• EBITDA ₹7.45 crore; EBITDA margin 16.0%.
• PAT ₹4.62 crore; PAT margin 9.9%.
• Basic EPS ₹7.78 for FY26.

Balance sheet & liquidity

• Total equity & liabilities ₹43.53 crore; cash ₹1.03 crore.
• Short-term borrowings ₹6.66 crore; equity funds ₹23.35 crore.
• Inventories ₹13.57 crore; trade receivables ₹18.76 crore.

Strategic outlook

• Manufacturing expansion targeted by March 2028 to 20% own manufacturing.
• Global expansion planned; LATAM and other regions by 2028-29.
• Pan-India footprint targeted by 2029; three growth pillars: Own Manufacturing, Global Expansion, Pan-India.

Governance & leadership

• Managing Director: Tejash M. Hathi; CFO: Kapil H. Chandarana.
• Independent Directors: Vikash R. Jobanputra; other directors listed.
• Company Secretary & Compliance: Mohini H. Gandhi.

Financials

• FY25-26 revenue ₹4,657.46 lakh; up 89.7% YoY.
• PAT ₹461.99 lakh; up 49.05% YoY.
• EBITDA ₹750.32 lakh; up 57.73% YoY.
• EPS ₹7.78; basic/diluted.
• Total expenses ₹4,033.35 lakh; scale-driven growth.
• Net cash from operating activities ₹(560.28) lakh.

Portfolio & Verticals

• Three verticals: Pharma Formulations, Consumer Products, International.
• Asset-light model; outsourced manufacturing; scalable.
• Portfolio grows from 140+ (2023) to 250+ (2026).
• 10,000+ doctors, 25,000+ retailers, 200+ distributors.
• Strategy: expand pan-India; build global footprint by 2030.

IPO & Capital Structure

• IPO: 18,60,000 shares at ₹70; ₹1,302 lakh raised.
• Listed on BSE SME on 30 Sep 2025; capital ₹6.86 crore.
• Bonus issue: 1,02,90,000 shares; capital ₹17.15 crore.
• Proposed preferential issue: up to 16,02,870 shares at ₹280; ₹44.88 crore.
• Floor price ₹280; valuation by CS Ambrish N Gandhi.
• Post-issue promoters 67.18%; public 32.82%.

IPO Proceeds Utilisation

• Capex ₹25.0 crore; Working capital ₹10.0 crore.
• General corporate ₹9.88 crore; IPO expenses ₹1.48 crore.
• Total IPO proceeds utilised ₹44.88 crore; no deviation.

Governance & Compliance

• Statutory auditors: ABK B & Co; term to 2029; no qualifications.
• Secretarial auditor: JPMK; MGT-14 filing delay resolved July 2026.
• Board committees: Audit, Nomination & Remuneration, Stakeholder Relationship.
• CSR not applicable; SME exemption from corporate governance disclosures.

Risks & Outlook

• Forward-looking statements subject to regulatory, market, FX, and input costs.
• Opportunities in portfolio expansion, new geographies, and consumer/export growth.
• Asset-light model increases reliance on contract manufacturers.

AGM & Shareholder Actions

• 16th AGM on 14 Sep 2026; VC/OAVM; cut-off 7 Sep 2026.
• Remote e-voting: 11-13 Sep 2026 via CDSL.
• Proxy facility not available; attendance via VC/OAVM.